NetraMark

Welcome to the NetraMark Board P.J. Haley #NetraMark, #Oncology, #Biotech, #AI https://lnkd.in/ewWcFVa9

Go Josh Spiegel, CFA !

Our CTO/CSO got quoted in the New York Post yesterday. Thank you Alex Tapscott

🔔 Meet us in Philadelphia! 🔔 NetraMark is thrilled to participate in the Alzheimer's Association International Conference (AAIC) 2024, where we’ll unveil our findings on machine learning for early detection of cognitive impairment. 📅 Save the Date: Monday, July 29, 2024 🕗 Time: 8:00 a.m.–4:15 p.m. EDT 🏛️ Location: Pennsylvania Convention Center 📌 Poster Presentation: #93236 🔬 Topic: Using Machine Learning to Explore Multimodal Digital Markers for Early Detection of Cognitive Impairment in Alzheimer’s Disease As a leader in generative AI for clinical trials, we are eager to present our latest findings and discuss their implications for Alzheimer’s diagnosis and treatment. The NetraMark team will be on-site for the entire conference, so please reach out to josh.spiegel@netramark.com if you’d like to meet with us. We look forward to engaging with fellow researchers, healthcare professionals, and stakeholders in the pursuit of advancing neurodegenerative disease research. #AAIC2024 #AlzheimersResearch #MachineLearning #HealthcareInnovation #Neuroscience #CognitiveHealth #NetraMark

NetraMark & NIMH Collaboration: AI to Identify Variables in Ketamine Clinical Trials with Challengingly Small Datasets We're excited to announce a new partnership with the National Institute of Mental Health (NIMH). Our NetraAI technology will be instrumental in identifying variables characterizing ketamine response, placebo response & adverse events. These insights will guide the design of future clinical trials in psychiatric conditions. Read more and explore the challenge of using AI on small datasets here> https://bit.ly/NetraMark

Ready to Transform Psychiatric Trial Outcomes with Predictive Accuracy Using NetraAI? See How at ASCP 2024 Breaking for #ASCP24: Prepare to redefine how you can modify inclusion/exclusion criteria to minimize placebo response in a clinical trial. Reduce the time, cost, and failure rates for developing urgently needed therapies for psychiatric indications. See how our AI-derived insights improve trial performance, all while increasing patient safety. Details? All will be unveiled at ASCP 2024! Want to optimize your trial designs? Let's connect in Miami Beach. Your data has never been this powerful…. Meet the team: Larry Alphs, Luca Pani, Joseph Geraci, Josh Spiegel, CFA Book Your Meeting Today: josh.spiegel@netramark.com

We provided a business update and highlighted several recent key accomplishments, including: 1) Launched NetraAI Lab; 2) Generated $1M CDN from signed contracts with leading biopharmaceutical companies; and 3) Presented data at two key medical conferences that demonstrate the power of NetraAI to identify novel biomarkers and improve clinical trial success.   "The power of our NetraAI platform, combined with the launch of our innovative NetraAI Lab offering, are advances that could impact clinical trial success rates,” said George Achilleos, NetraMark CEO. “We are executing our key objectives early in 2024. We look forward to expanding our business and scientific momentum by building upon the exciting opportunities ahead."   See the full press release here: https://bit.ly/3TIFVzh  #NetraAI #NetraMark #ClinicalTrials

Yesterday, we announced a new NetraAI Lab contract with a pharmaceutical company’s Phase 2 clinical trial. The company will use NetraAI to analyze its data and deliver key insights and testable hypotheses with the potential to de-risk further development its asset.   "This contract demonstrates the interest by the industry to use their own data to validate leading edge solutions, such as ours," said Josh Spiegel, CFA, President of NetraMark.    Read our press release to learn more about yesterday's announcement: https://bitly.ws/3fG7q   #NetraAI #ClinicalTrials #AI

We are thrilled to have presented new NetraAI data at AD/PD - Advances in Science & Therapy!   Data demonstrated NetraAI’s ability to identify multiple markers associated with Parkinson’s disease pathogenesis, leading to enhanced disease knowledge for improving treatment strategies.   We would also like to thank The Michael J. Fox Foundation for Parkinson's Research for collaborating and providing us with the patient dataset for analysis.   For additional information about the NetraAI, please contact josh.spiegel@netramark.com.   To learn more about our AD/PD 2024 data presentation, read our press release here: https://bitly.ws/3fyE8   #NetraAI #ClinicalTrials #AI #ADPD2024 #parkinsons

We are excited to present new data demonstrating our proprietary NetraAI clinical trial solution at AD/PD - Advances in Science & Therapy 2024 taking place March 5-9 in Lisbon, Portugal.   The poster presentation will showcase the potential of NetraAI to generate novel insights into key drivers of Parkinson's disease.   Our CMO, Larry Alphs, will share the latest Parkinson's disease insights that NetraAI has generated at the conference.   For additional information about the NetraAI, please contact josh.spiegel@netramark.com.   Read more about our poster presentation at AD/PD 2024 in our press release here: https://bitly.ws/3eBcG    #NetraAI #ClinicalTrials #AI #ADPD2024 #parkinsons